1824-97-1

Basic information

• Product Name: .beta.-D-Xylofuranoside, methyl
• Synonyms: .beta.-D-Xylofuranoside, methyl;Methyl b-D-xylofuranoside;b-D-Xylofuranoside, Methyl;Methyl beta-D-xylofuranoside
• CAS NO: 1824-97-1
• Molecular Formula: C₆H₁₂O₅
• Molecular Weight: 164.16
• Mol File: 1824-97-1.mol
• Article Data: 85

Chemical Properties

• Melting Point: 45 °C
• Boiling Point: 348.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.40
• PKA: 13.14±0.70(Predicted)
• CAS DataBase Reference: .beta.-D-Xylofuranoside, methyl(CAS DataBase Reference)
• NIST Chemistry Reference: .beta.-D-Xylofuranoside, methyl(1824-97-1)
• EPA Substance Registry System: .beta.-D-Xylofuranoside, methyl(1824-97-1)

Safety Data

• Hazardous Substances Data: 1824-97-1(Hazardous Substances Data)

Usage

General Description

.beta.-D-Xylofuranoside, methyl is a chemical compound with the molecular formula C6H12O5. It is a methylated derivative of the sugar xylose, and it consists of a five-membered ring with four carbon atoms and one oxygen atom. .beta.-D-Xylofuranoside, methyl is often used in organic synthesis and as a building block for the production of various pharmaceuticals and natural products. It is a white, crystalline powder that is soluble in water and has a sweet taste. .beta.-D-Xylofuranoside, methyl is also known for its potential as a substrate for enzymatic reactions and as a chiral building block in the synthesis of complex molecules.

Upstream product

• 67-56-1 methanol 
• 58-86-6 D-xylose 
• 1114-34-7 D-lyxose 
• 87-72-9 D-lyxose 
• 50-69-1 D-ribose 
• 189129-08-6 C₃₀H₂₆N₄O₈ 
• 532-20-7 D-Ribose 
• 36468-53-8 β-D-ribofuranose 
• 532-20-7 D-xylofuranose 
• 75-36-5 acetyl chloride 
• 5328-37-0 L-arabinose 
• 609-06-3 L-xylose 
• 87-72-9 D-Xylose 
• 63846-98-0 1,2-O-(1-Methylethylidene)-α-D-ribo-pentodialdo-1,4-furanose 

Downstream Products

• 138383-82-1 methyl 5-O-trityl-2,3-O-dimesyl-β-D-xylofuranoside 
• 83376-69-6 methyl 2,3-di-O-methyl-D-riboside 
• 83376-70-9 methyl 2,5-di-O-methyl-D-riboside 
• 83376-68-5 methyl 3,5-di-O-methyl-D-riboside 
• 2296-41-5 methyl 2,3,5-tri-O-methyl-D-ribofuranoside 
• 58763-00-1 ((3aR,4R,6S,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 4099-85-8 ((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 2296-41-5 methyl-tri-O-methyl-arabinofuranoside 
• 874770-89-5 [6-methoxy-2-(4-methoxyphenyl)tetrahydrofuro[3,4-d][1,3]-dioxol-4-yl]methanol 
• 102207-93-2 methyl 2,3-Di-O-benzyl-β-D-ribo-pentodialdofuranoside 
• 70831-62-8 methyl 2,3-di-O-benzyl-β-D-ribofuranoside 
• 532401-39-1 methyl 2,3-di-O-benzyl-α-D-ribofuranoside 
• 532401-43-7 1-((2S,3S,4R,5R)-3,4-Bis-benzyloxy-5-methoxy-tetrahydro-furan-2-yl)-propenone 
• 532401-42-6 (2S,3S,4R,5R)-3,4-Bis-benzyloxy-5-methoxy-tetrahydro-furan-2-carboxylic acid methoxy-methyl-amide 

Relevant articles and documents

MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF

The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.

BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

Substituted pyrazole compound, preparation method, pharmaceutical composition and applications thereof

The invention discloses a substituted pyrazole compound represented by a formula I, and a preparation method, a pharmaceutical composition and applications thereof, wherein the compound has characteristics of good stability, excellent solubility, low cytotoxicity and remarkable neuroprotective effect, can effectively prevent and treat nerve cell injury, and is an ideal medicinal compound for preventing or treating cerebral stroke, cerebral embolism, cerebral stroke sequelae, cerebral stroke dyskinesia, mitochondrial encephalomyopathy and amyotrophic lateral sclerosis of spinal cord.